L3VLUP
ProSign in

TEVA · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TEVAJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TEVA
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterTEVAJNJ
Q3 20207 holders, $2.1bn30 holders, $26.2bn
Q4 20205 holders, $2.2bn32 holders, $26.6bn
Q1 20218 holders, $2.6bn31 holders, $25.3bn
Q2 20217 holders, $2.1bn37 holders, $25.6bn
Q3 20216 holders, $1.7bn40 holders, $24.1bn
Q4 20214 holders, $1.1bn33 holders, $25.2bn
Q1 20229 holders, $1.4bn35 holders, $28.2bn
Q2 202211 holders, $913m33 holders, $26.9bn
Q3 202211 holders, $1.4bn36 holders, $25.4bn
Q4 202211 holders, $1.7bn35 holders, $27.6bn
Q1 20238 holders, $1.3bn42 holders, $24.5bn
Q2 202310 holders, $184m38 holders, $25.0bn
Q3 202313 holders, $384m37 holders, $18.9bn
Q4 202310 holders, $373m31 holders, $19.0bn
Q1 202416 holders, $666m32 holders, $19.7bn
Q2 202422 holders, $1.8bn35 holders, $20.4bn
Q3 202422 holders, $2.3bn28 holders, $22.3bn
Q4 202418 holders, $3.0bn37 holders, $20.4bn
Q1 202512 holders, $2.0bn32 holders, $20.5bn
Q2 202511 holders, $1.8bn31 holders, $18.4bn
Q3 202514 holders, $964m32 holders, $23.7bn
Q4 202516 holders, $2.1bn29 holders, $27.8bn
Q1 202614 holders, $2.0bn34 holders, $35.6bn
Q2 202614 holders, $2.4bn33 holders, $39.1bn
TEVA

Teva Pharmaceutical Inds LTD

Holders
14
Reported value
$964m
Buyers
9
Sellers
4

Breadth +5 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$23.7bn
Buyers
17
Sellers
13

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 41 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TEVA (9)

ARK Investment Management LLC, Farallon Capital Management LLC, Glenview Capital Management LLC, Greenlight Capital, Maverick Capital Ltd, Moore Capital Management LP, Rokos Capital Management LLP, Steadfast Capital Management LP, Viking Global Investors LP

Only JNJ (27)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →